Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

QN201908051111-B

ABSTRACT: QN201908051111-B

TISSUE(S): ['lung']

SUBMITTER: Yifan Zhao

PROVIDER: OEX00010427 | NODE | 2021-11-23

REPOSITORIES: NODE

ACCESS DATA

Json Xml

Similar Datasets

Tyrosine Kinase Inhibitor-induced cardiotoxicity in hiPSC derived cardiomyocytes - pilot dataset (qPCR validation)

Project description: Not available

2018-03-20 | LDS-1517 | LINCS

Breast Cancer Profiling Project, Gene Expression 1: Baseline mRNA sequencing on 35 breast cell lines

Project description: Not available

2018-07-06 | LDS-1530 | LINCS

L1000 Consensus Signatures - CRISPR perturbagens

Project description: Not available

| LDS-1586 | LINCS

L1000 Consensus Signatures - shRNA perturbagens

Project description: Not available

| LDS-1585 | LINCS

Random-primed mRNA-sequencing transcriptomic dataset for 70 primary human cardiomyocyte cell samples

Project description:Each of 70 cell samples either at the control condition or treated with FDA-approved cancer drugs is sequenced by the single-ended random-primed mRNA-sequencing method with a read length of 100 base pairs, and a total of 70 raw sequence data files in the FASTQ format are generated. These sequence data files are then analyzed by a high-performance computational pipeline and ranked lists of gene signatures and biological processes related to drug-induced cardiotoxicity are generated for each drug. The raw sequence datasets and the analysis results have been carefully controlled for data quality, and they are made publicly available at the Gene Expression Omnibus (GEO) database repository of NIH. As such, this broad drug-stimulated transcriptomi dataset is valuable for the prediction of drug toxicities and their mitigations.

2020-11-09 | LDS-1587 | LINCS

3'-DGE mRNA-sequencing transcriptomic dataset for 914 primary human cardiomyocyte cell samples

Project description:Each of 914 cell samples either at the control condition or treated with FDA-approved cancer drugs is sequenced by the single-ended 3'-DGE mRNA-sequencing method with a read length of 46 base pairs, and a total of 914 raw sequence data files in the FASTQ format are generated. These sequence data files are then analyzed by a high-performance computational pipeline and ranked lists of gene signatures and biological processes related to drug-induced cardiotoxicity are generated for each drug. The raw sequence datasets and the analysis results have been carefully controlled for data quality, and they are made publicly available at the Gene Expression Omnibus (GEO) database repository of NIH. As such, this broad drug-stimulated transcriptomi dataset is valuable for the prediction of drug toxicities and their mitigations.

2020-11-09 | LDS-1592 | LINCS

L1000 Dataset -small molecule, CRISPR perturbagens- LINCS Phase 2 (December 2015)

Project description:Transcriptional profiles of multiple cell and perturbation types: 23 cells are treated with 311 chemical perturbagens and CRISPR reagents. The expression level for 978 representative genes is measured.

2015-12-31 | LDS-1293 | LINCS

L1000 Dataset -small molecule perturbagens- LINCS Joint Project

Project description:Transcriptional profiles of cultured human breast cancer cell lines treated with small molecules: 5 cell lines are treated with 109 small molecules and the expression of 978 representative genes is measured, as a part of the LINCS Joint Project.

2014-05-30 | LDS-1203 | LINCS

iPSC (Exp 1) - ALS, SMA and Control (unaffected) subject-derived iPSC lines - RNA-seq

Project description:RNA-Seq was carried out on isolated mRNA obtained from induced Pluripotnent Stem Cells (iPSC) cell lines. These lines were derived from ALS, SMA and Control (unaffected) individuals (three of each).

2016-09-01 | LDS-1356 | LINCS

L1000 MCF10A Deep Dive Dataset: treatment with ligands

Project description: Not available

2021-01-20 | LDS-1603 | LINCS